Teva Pharmaceuticals and mAbxience Join Hands to Develop Biosimilar Candidates for Treating Oncology Indications
Shots:
- Teva Pharmaceuticals and mAbxience have signed a strategic licensing agreement across various markets incl. the EU and the US to develop a biosimilar product that is under development as a treatment for various oncology indications
- As per the agreement, mAbxience will develop and produce the candidates by utilizing the knowledge of biosimilar development & its state-of-the-art along with current Good Manufacturing Practice (cGMP)-approved facilities in Spain & Argentina
- Furthermore, Teva will be responsible for all the regulatory and commercialization activities across the designated areas for easy access to the patients
Ref: Teva Pharmaceuticals | Image: Teva Pharmaceuticals
Related News:- Alvotech and Teva’s Simlandi (Biosimilar, Humira) Receives the US FDA’s Approval for the Treatment of Multiple Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
